Europeans are immune to XMRV

Labs in Europe reported earlier this year that they haven't been able to replicate the XMRV findings in patients with chronic fatigue syndrome or prostate cancer.
Buy the way, there is still time to invest in ARV manufacturers, as Researchers at Emory University and the University of Utah published a study last week showing that XMRV may be treatable with drugs that treat HIV
Theoretically possible approval of ARVs at some point in the future for chronic fatigue syndrome and prostate cancer treatment will prevent social security system from going bankrupt,